Last reviewed · How we verify
XL820
At a glance
| Generic name | XL820 |
|---|---|
| Sponsor | Exelixis |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib (PHASE2)
- Study of XL820 Given Orally Daily to Subjects With Solid Tumors (PHASE1)
- Study of XL820 in Adults With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XL820 CI brief — competitive landscape report
- XL820 updates RSS · CI watch RSS
- Exelixis portfolio CI